TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

MEDIFAST INC (MED)

Consumer Cyclical Personal Services
9.90 $
-0.5% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at MEDIFAST INC.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 4 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
9.90$
Open
9.80$
Day High
10.00$
Day Low
9.60$
Volume
103,360shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
9.50 $ 14.60 $
07/23/2026 09/18/2025

Current price 9.90 $ — 8% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.1$B
Shares Outstanding
11Mio.
Float
69.3%
Beta
0.7

Performance

Perf. 1M
-18.60%
Perf. 3M
9.70%
Perf. 6M
-5.10%
YTD Performance (%)
-0.60%
52-Week-High Distance
-34.0%
Perf. 1Y
-28.61%
Perf. 3Y
-90.15%
Perf. 5Y
-96.13%
Perf. 10Y
-64.03%
Perf. Since Inception
136.11%

Technical Indicators

MA 38 Days
10.70$
MA 50 Days
11.20$
MA 200 Days
11.20$
RSI (14)
39.6
Volatility 30 Days
39.4%
Volatility 250 Days
40.1%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
12.5
PEG
1.0
P/B
0.6
P/S
0.3
EV/EBITDA
0.3
Price/FCF

Profitability

Gross Margin
70.1%
EBIT Margin
Net Margin
-5.8%
Return on Equity
-9.8%
Return on Assets
-4.3%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
0.1
fortress balance sheet
Altman Z″
13.05
Piotroski
3 out of 9

Growth

Sales Growth Last Quarter
-34.30%
EPS Growth Last Quarter
-87.20%
Sales Growth (Year)
-35.96%
Forward Sales Growth
-8.47%
Forward EPS Growth
67.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
1
RS Rating
23
EPS Rating
4
Piotroski
3 out of 9
Fundamental Rating
D (37 out of 100)
fortress balance sheet
Altman Z″
13.05

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 9.90 $
Price Target (average) 12.00 $

The price target sits 21.2% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

3. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.67 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 119.0 $M Q4 2025: Q1 · 115.7 $M Q1 2025: Q2 · 105.6 $M Q2 2025: Q3 · 89.4 $M Q3 2025: Q4 · 75.1 $M Q4 2026: Q1 · 76.0 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.07 -86.80 119 -37.70 0.70 -5 -7
2025: Q1 -0.07 -109.30 116 -33.80 -0.70 3 2
2025: Q2 0.22 106 -37.40 2.30 -3 -5
2025: Q3 -0.21 -299.90 89 -36.20 -2.50 12 11
2025: Q4 -1.65 -2,360.40 75 -36.90 -24.10 -5 -7
2026: Q1 -0.19 76 -34.30 -2.80 0 -1
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Medifast, Inc. ist über seine Tochtergesellschaften ein Gesundheits- und Wellnessunternehmen, das gewohnheitsbasierte und coachgeführte Lifestyle-Lösungen zur Gewichtsabnahme in den USA anbietet.

Employees380
HeadquartersBaltimore, MD
Websitemedifastinc.com
IPO Date31. Dec 1993

Management

Management
Name Title Birth Year
Nicholas M. Johnson CEO & President 1980
James P. Maloney CPA Chief Financial Officer 1968
Jonathan Barrett MacKenzie VP of Finance & Chief Accounting Officer 1972
Steven Zenker Vice President of Investor Relations
Claudia C. Greninger Chief Human Resources Officer 1974

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?